-
Obsessive-Compulsive Disorder Prevalence in Parkinson’s Disease Caregivers
-
Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit
-
Odor-specific symptoms in Parkinson’s disease – UPSIT odor identification status versus clinical severity.
-
Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
-
One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
-
One-year longitudinal decline in spatial location memory in Huntington’s disease
-
One-Year Outcomes of Multitarget Thalamic and Pallidal Deep Brain Stimulation in Unilateral Dystonia
-
Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON
-
Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease
-
Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease
-
Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial
-
Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.
-
Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion
-
Opportunities for Medical Knowledge Self-Assessment in Movement Disorder Fellowship
-
Opsoclonus after Covid-19 infection
-
Optical Coherence Tomography Findings in Multiple System Atrophy: Insights into Disease Subtypes, Clinical Correlations, and Dopaminergic Degeneration
-
Optimal measuring height and validation of 2D-LiDAR based analysis system for spatiotemporal gait parameters
-
OPTN gene associated with corticobasal syndrome: a novel multi-exon deletion and literature review
-
Optogenetic Deep Brain Stimulation Rescues Motor Behavior in a Rat Model of Mild Parkinson’s Disease
-
Oral health in Parkinson’s disease patients from countries with different economies: preliminary results of the OralPark study.
-
ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
-
Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine
-
Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss
-
Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film
-
Orthostatic hypotension in age-related neurodegenerative diseases: a bibliometric study from 2007 to 2023
-
Orthostatic Hypotension is Associated with Worse Verbal Letter Fluency and Lower Neural Efficiency While Upright in Parkinson’s Disease: A Pilot Study
-
Orthostatic Hypotension:a Clinical Marker for the Body-First Subtype of Patients with Parkinson’s Disease
-
Oscillatory network mapping of deep brain stimulation outcomes in Parkinson’s disease
-
Oscillatory signatures of genetic Parkinson’s disease patients in subthalamic macroelectrode recordings
-
Outcomes in Patients with Parkinsonism Treated for Acute Agitation with Intravenous Benzodiazepines Compared to Parenteral Antipsychotics While Inpatient
-
Outpatient Treatment of Functional Movement Disorders
-
Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations
2024 International Congress
September 27-October 1, 2024. Philadelphia, PA.